Physician profile
Edith Graves
NPI 1396826129
$1,455.87
in general payments reported to CMS, 2019-2025
30 companies · $38.12 in 2025
The $38.12 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.05 · 2021: $68.49 · 2022: $243 · 2023: $420 · 2024: $647 · 2025: $38.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.55 | 2019-2025 | |
| Abbvie INC. | $104.94 | 2023-2025 | |
| Gilead Sciences, INC. | $98.62 | 2022-2024 | Trodelvy |
| Amgen INC. | $96.39 | 2021-2022 | |
| Celgene Corporation | $92.19 | 2024 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $91.39 | 2023-2024 | Tecvayli, Talvey, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $70.66 | 2022-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $66.39 | 2021-2024 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $64.15 | 2024 | Enhertu |
| Merck Sharp & Dohme LLC | $55.51 | 2024 | Keytruda |
| Beigene USA, INC. | $54.99 | 2023-2024 | Brukinsa, Tevimbra |
| Regeneron Healthcare Solutions, INC. | $54.85 | 2023-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $53.65 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $51.36 | 2023-2024 | Enhertu, Lynparza |
| Seagen INC. | $46.00 | 2022-2023 | Tukysa, Padcev |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $38.73 | 2022-2023 | Fotivda |
| Deciphera Pharmaceuticals INC. | $38.32 | 2024 | Qinlock, Tgct |
| Genentech USA, INC. | $28.87 | 2019-2023 | Tecentriq |
| Mirati Therapeutics, INC. | $27.91 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $22.76 | 2024 | |
| Sobi, INC | $21.97 | 2024 | |
| Incyte Corporation | $21.22 | 2022 | |
| Morphosys, US INC. | $20.00 | 2023 | Monjuvi |
| Astellas Pharma US INC | $19.93 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.22 | 2021 | |
| Springworks Therapeutics, INC. | $17.70 | 2024 | Ogsiveo |
| Karyopharm Therapeutics INC. | $14.61 | 2022 | |
| Kite Pharma, INC. | $13.35 | 2023 | |
| Myovant Sciences INC. | $12.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.